HYAL1
Basic information
Region (hg38): 3:50299890-50312381
Links
Phenotypes
GenCC
Source:
- mucopolysaccharidosis type 9 (Definitive), mode of inheritance: AR
- mucopolysaccharidosis type 9 (Strong), mode of inheritance: AR
- mucopolysaccharidosis type 9 (Limited), mode of inheritance: AR
- mucopolysaccharidosis type 9 (Supportive), mode of inheritance: AR
- mucopolysaccharidosis type 9 (Strong), mode of inheritance: AR
- mucopolysaccharidosis type 9 (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Mucopolysaccharidosis type IX | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Craniofacial; Dermatologic; Musculoskeletal | 8793927; 10339581 |
ClinVar
This is a list of variants' phenotypes submitted to
- Deficiency_of_hyaluronoglucosaminidase (361 variants)
- not_specified (55 variants)
- not_provided (14 variants)
- HYAL1-related_disorder (8 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HYAL1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000033159.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 172 | 179 | ||||
missense | 131 | 10 | 148 | |||
nonsense | 14 | 19 | ||||
start loss | 0 | |||||
frameshift | 16 | 10 | 28 | |||
splice donor/acceptor (+/-2bp) | 1 | |||||
Total | 31 | 16 | 141 | 182 | 5 |
Highest pathogenic variant AF is 0.0000204449
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HYAL1 | protein_coding | protein_coding | ENST00000266031 | 3 | 12493 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000191 | 0.907 | 125711 | 0 | 37 | 125748 | 0.000147 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.315 | 252 | 266 | 0.946 | 0.0000173 | 2812 |
Missense in Polyphen | 93 | 98.118 | 0.94784 | 1105 | ||
Synonymous | 0.00526 | 108 | 108 | 0.999 | 0.00000642 | 926 |
Loss of Function | 1.52 | 8 | 14.2 | 0.564 | 6.25e-7 | 144 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000330 | 0.000329 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000218 | 0.000217 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000151 | 0.000149 |
Middle Eastern | 0.000218 | 0.000217 |
South Asian | 0.000263 | 0.000261 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: May have a role in promoting tumor progression. May block the TGFB1-enhanced cell growth. {ECO:0000269|PubMed:12084718}.;
- Pathway
- Lysosome - Homo sapiens (human);Glycosaminoglycan degradation - Homo sapiens (human);Metabolism of carbohydrates;CS/DS degradation;Chondroitin sulfate/dermatan sulfate metabolism;Glycosaminoglycan metabolism;chondroitin sulfate degradation (metazoa);Metabolism;dermatan sulfate degradation (metazoa)
(Consensus)
Intolerance Scores
- loftool
- 0.716
- rvis_EVS
- 0.11
- rvis_percentile_EVS
- 62
Haploinsufficiency Scores
- pHI
- 0.108
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.468
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0278
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hyal1
- Phenotype
- skeleton phenotype; immune system phenotype; respiratory system phenotype; liver/biliary system phenotype;
Gene ontology
- Biological process
- response to reactive oxygen species;carbohydrate metabolic process;inflammatory response;response to virus;positive regulation of epithelial cell migration;chondroitin sulfate catabolic process;hyaluronan metabolic process;hyaluronan biosynthetic process;hyaluronan catabolic process;positive regulation of cell growth;negative regulation of cell growth;cellular response to platelet-derived growth factor stimulus;cellular response to fibroblast growth factor stimulus;positive regulation of angiogenesis;positive regulation of cell adhesion;positive regulation of growth;response to antibiotic;viral entry into host cell;positive regulation of epithelial cell proliferation;cartilage development;embryonic skeletal joint morphogenesis;cellular response to interleukin-1;cellular response to tumor necrosis factor;cellular response to pH;cellular response to UV-B;positive regulation of G1/S transition of mitotic cell cycle;positive regulation of hyaluranon cable assembly
- Cellular component
- extracellular space;cytoplasm;lysosome;cytoplasmic vesicle;hyaluranon cable;lysosomal lumen;extracellular exosome
- Molecular function
- virus receptor activity;hyalurononglucosaminidase activity;transcription factor binding;hyaluronan synthase activity